{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for tazemetostat in Standardized Name (approximate match)
Showing 1 - 8 of 8 results
Status:
US Approved Rx
(2020)
Source:
NDA211723
(2020)
Source URL:
First approved in 2020
Source:
NDA211723
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tazemetostat (EPZ-6438) is a selective inhibitor of histone-lysine N-methyltransferase EZH2. The drug is under clinical development (phase II) for the treatment of Diffuse Large B Cell Lymphoma, Malignant Mesothelioma and Synovial Sarcoma.
Status:
US Approved Rx
(2020)
Source:
NDA211723
(2020)
Source URL:
First approved in 2020
Source:
NDA211723
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tazemetostat (EPZ-6438) is a selective inhibitor of histone-lysine N-methyltransferase EZH2. The drug is under clinical development (phase II) for the treatment of Diffuse Large B Cell Lymphoma, Malignant Mesothelioma and Synovial Sarcoma.
Status:
US Approved Rx
(2020)
Source:
NDA211723
(2020)
Source URL:
First approved in 2020
Source:
NDA211723
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tazemetostat (EPZ-6438) is a selective inhibitor of histone-lysine N-methyltransferase EZH2. The drug is under clinical development (phase II) for the treatment of Diffuse Large B Cell Lymphoma, Malignant Mesothelioma and Synovial Sarcoma.
Status:
US Approved Rx
(2020)
Source:
NDA211723
(2020)
Source URL:
First approved in 2020
Source:
NDA211723
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tazemetostat (EPZ-6438) is a selective inhibitor of histone-lysine N-methyltransferase EZH2. The drug is under clinical development (phase II) for the treatment of Diffuse Large B Cell Lymphoma, Malignant Mesothelioma and Synovial Sarcoma.
Status:
US Approved Rx
(2020)
Source:
NDA211723
(2020)
Source URL:
First approved in 2020
Source:
NDA211723
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tazemetostat (EPZ-6438) is a selective inhibitor of histone-lysine N-methyltransferase EZH2. The drug is under clinical development (phase II) for the treatment of Diffuse Large B Cell Lymphoma, Malignant Mesothelioma and Synovial Sarcoma.
